Skip to content

Study · Randomized controlled trial · n = 283 · 1995

9 results

Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.

Vogelzang NJ, Chodak GW, Soloway MS, Block NL, Schellhammer PF, Smith JA Jr, Caplan RJ, Kennealey GT

Urology1 Aug 1995Cited by 94 (Europe PMC)

PMID7624991 (opens in a new tab)DOI10.1016/s0090-4295(99)80197-6 (opens in a new tab)PepBankPUB-07624991
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with stage D2 prostate cancer, objective response was similar with goserelin and orchiectomy (82% versus 77%).

    In plain wordsIn patients with prostate cancer, response was similar with goserelin and orchiectomy.

    Peptide
    Goserelin
    Outcome
    Direction not reportedObjective response
    Study

    n = 283

    Comparator
    Orchiectomy
    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.6 mg every 28 daysAs given in this study (human).

    Measurements

    Objective response
    82%
    goserelin
    Objective response
    77%
    orchiectomy

    Source sentences

    Summary
    The goserelin and orchiectomy groups had similar results for objective response (82% versus 77%) and had similar medial times to treatment failure (52 versus 53 weeks) and survival (119 versus 136 weeks).
    3 context sentences
    Summary · context
    To compare the efficacy and safety of goserelin and orchiectomy in patients with stage D2 prostate cancer.
    Summary · context
    A randomized, open, multicenter study was conducted in 283 patients.
    Summary · context
    Patients were allocated to goserelin, 3.6 mg every 28 days or to orchiectomy.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with stage D2 prostate cancer, treatment failure times were similar with goserelin and orchiectomy (52 versus 53 weeks).

    In plain wordsIn patients with prostate cancer, treatment failure times were similar with goserelin and orchiectomy.

    Peptide
    Goserelin
    Outcome
    Direction not reportedTime to treatment failure
    Study

    n = 283

    Comparator
    Orchiectomy
    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.6 mg every 28 daysAs given in this study (human).

    Measurements

    Median time to treatment failure
    52 weeks
    goserelin
    Median time to treatment failure
    53 weeks
    orchiectomy

    Source sentences

    Summary
    The goserelin and orchiectomy groups had similar results for objective response (82% versus 77%) and had similar medial times to treatment failure (52 versus 53 weeks) and survival (119 versus 136 weeks).
    3 context sentences
    Summary · context
    To compare the efficacy and safety of goserelin and orchiectomy in patients with stage D2 prostate cancer.
    Summary · context
    A randomized, open, multicenter study was conducted in 283 patients.
    Summary · context
    Patients were allocated to goserelin, 3.6 mg every 28 days or to orchiectomy.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with stage D2 prostate cancer, survival was similar with goserelin and orchiectomy (119 versus 136 weeks).

    In plain wordsIn patients with prostate cancer, survival was similar with goserelin and orchiectomy.

    Peptide
    Goserelin
    Outcome
    Direction not reportedSurvival
    Study

    n = 283

    Comparator
    Orchiectomy
    Outcome group
    Mortality · Cancer
    Studied dose
    3.6 mg every 28 daysAs given in this study (human).

    Measurements

    Survival
    119 weeks
    goserelin
    Survival
    136 weeks
    orchiectomy

    Source sentences

    Summary
    The goserelin and orchiectomy groups had similar results for objective response (82% versus 77%) and had similar medial times to treatment failure (52 versus 53 weeks) and survival (119 versus 136 weeks).
    3 context sentences
    Summary · context
    To compare the efficacy and safety of goserelin and orchiectomy in patients with stage D2 prostate cancer.
    Summary · context
    A randomized, open, multicenter study was conducted in 283 patients.
    Summary · context
    Patients were allocated to goserelin, 3.6 mg every 28 days or to orchiectomy.
  4. 04HumanRandomized controlled trialSafety outcome

    In patients with stage D2 prostate cancer, pain was common with both goserelin and orchiectomy.

    In plain wordsIn patients with prostate cancer, pain was common in both groups.

    Peptide
    Goserelin
    Outcome
    Direction not reportedPain
    Study

    n = 283

    Comparator
    Orchiectomy
    Outcome group
    Adverse events · Whole body
    Studied dose
    3.6 mg every 28 daysAs given in this study (human).

    Source sentences

    Summary
    Common adverse events in both groups were pain, hot flushes, and lower urinary tract symptoms.
    3 context sentences
    Summary · context
    To compare the efficacy and safety of goserelin and orchiectomy in patients with stage D2 prostate cancer.
    Summary · context
    A randomized, open, multicenter study was conducted in 283 patients.
    Summary · context
    Patients were allocated to goserelin, 3.6 mg every 28 days or to orchiectomy.
  5. 05HumanRandomized controlled trialSafety outcome

    In patients with stage D2 prostate cancer, hot flushes were common with both goserelin and orchiectomy.

    In plain wordsIn patients with prostate cancer, hot flushes were common in both groups.

    Peptide
    Goserelin
    Outcome
    Direction not reportedHot flushes
    Study

    n = 283

    Comparator
    Orchiectomy
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    3.6 mg every 28 daysAs given in this study (human).

    Source sentences

    Summary
    Common adverse events in both groups were pain, hot flushes, and lower urinary tract symptoms.
    3 context sentences
    Summary · context
    To compare the efficacy and safety of goserelin and orchiectomy in patients with stage D2 prostate cancer.
    Summary · context
    A randomized, open, multicenter study was conducted in 283 patients.
    Summary · context
    Patients were allocated to goserelin, 3.6 mg every 28 days or to orchiectomy.
  6. 06HumanRandomized controlled trialSafety outcome

    In patients with stage D2 prostate cancer, lower urinary tract symptoms were common with both goserelin and orchiectomy.

    In plain wordsIn patients with prostate cancer, lower urinary tract symptoms were common in both groups.

    Peptide
    Goserelin
    Outcome
    Direction not reportedLower urinary tract symptoms
    Study

    n = 283

    Comparator
    Orchiectomy
    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    3.6 mg every 28 daysAs given in this study (human).

    Source sentences

    Summary
    Common adverse events in both groups were pain, hot flushes, and lower urinary tract symptoms.
    3 context sentences
    Summary · context
    To compare the efficacy and safety of goserelin and orchiectomy in patients with stage D2 prostate cancer.
    Summary · context
    A randomized, open, multicenter study was conducted in 283 patients.
    Summary · context
    Patients were allocated to goserelin, 3.6 mg every 28 days or to orchiectomy.
  7. 07HumanNon-randomized trialEfficacy outcome

    In patients with stage D2 prostate cancer, testosterone fell to castrate levels by week 4 with goserelin and orchiectomy.

    In plain wordsIn patients with prostate cancer, testosterone fell to castrate levels by week 4 in both groups.

    Peptide
    Goserelin
    Outcome
    DecreaseSerum testosterone
    Study

    n = 283

    Comparator
    Baseline
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.6 mg every 28 daysAs given in this study (human).

    Source sentences

    Summary
    Serum testosterone decreased from baseline to castrate levels by week 4 in each group and remained below castrate levels thereafter.
    3 context sentences
    Summary · context
    To compare the efficacy and safety of goserelin and orchiectomy in patients with stage D2 prostate cancer.
    Summary · context
    A randomized, open, multicenter study was conducted in 283 patients.
    Summary · context
    Patients were allocated to goserelin, 3.6 mg every 28 days or to orchiectomy.
  8. 08HumanNon-randomized trialEfficacy outcome

    In patients with stage D2 prostate cancer, acid phosphatase decreased in both the goserelin and orchiectomy groups.

    In plain wordsIn patients with prostate cancer, acid phosphatase decreased in both groups.

    Peptide
    Goserelin
    Outcome
    DecreaseAcid phosphatase
    Study

    n = 283

    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.6 mg every 28 daysAs given in this study (human).

    Source sentences

    Summary
    Acid phosphatase and alkaline phosphatase concentrations also decreased in each group.
    3 context sentences
    Summary · context
    To compare the efficacy and safety of goserelin and orchiectomy in patients with stage D2 prostate cancer.
    Summary · context
    A randomized, open, multicenter study was conducted in 283 patients.
    Summary · context
    Patients were allocated to goserelin, 3.6 mg every 28 days or to orchiectomy.
  9. 09HumanNon-randomized trialEfficacy outcome

    In patients with stage D2 prostate cancer, alkaline phosphatase decreased in both the goserelin and orchiectomy groups.

    In plain wordsIn patients with prostate cancer, alkaline phosphatase decreased in both groups.

    Peptide
    Goserelin
    Outcome
    DecreaseAlkaline phosphatase
    Study

    n = 283

    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.6 mg every 28 daysAs given in this study (human).

    Source sentences

    Summary
    Acid phosphatase and alkaline phosphatase concentrations also decreased in each group.
    3 context sentences
    Summary · context
    To compare the efficacy and safety of goserelin and orchiectomy in patients with stage D2 prostate cancer.
    Summary · context
    A randomized, open, multicenter study was conducted in 283 patients.
    Summary · context
    Patients were allocated to goserelin, 3.6 mg every 28 days or to orchiectomy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.